SEPLIX

Serratiopeptidase 10mg

Each coated tablet contains: Serratiopeptidase (equivalent to 20,000 U) 10mg.

Serratiopeptidase :

Serratiopeptidase is a protein (proteolytic) enzyme isolated from the non-pathogenic enterobacteria Serratia E15 found in silkworms. Serratiopeptidase helps the fully-grown butterfly to escape from the cocoon. Serratiopeptidase has a particular affinity for dead protein molecules. Serratiopeptidase is known as proteolytic enzyme as the enzyme digests or breaks down proteib debris from toxins and inflammation. Serratiopeptidase digests away scar tissues, blood clots, cysts, mucus, arterial plaque and inflammation in all forms without side effects, It has been used successfully for almost 40 years in Japan and Europe for pain and inflammation due to arthritis, trauma, surgery, sinusitis, bronchitis, carpal tunnel and painful swelling of the breasts. There is some preliminary indication that it may be useful for atherosclerosis.

Therapeutic action :

Enzymatic compound with anti-inflammatory and anti-edematous properties. Bronchial secretion fluidifier.

Indications:

Trauma Surgeries :

In sports injuries, sprains, lacerations, fractures and dislocation. Reduces inflammation abd helps faster healing and repair of injured tissues.

Surgery :

Reduces post operative oedema at injection sites. Reduces internal tissue oedema caused by post operative handling. Reduction in oedema reduces chances of rupture ar tissue site as well as risk of graft rejection.

Plastic Surgery :

Reduces post operative oedema and restores microcirculation at the site of graft rejection,

Respiratory Medicine :

Breaks down complex sputum molecules in smaller peptides with lower viscosity, helping in expectorating them more easily. Reduced viscosity of secretions helps in better antibiotic penetration to enable control over stubborn infections like bronchitis, lung abscess and broncheitasis.

Infections :

Mucolytic activity in sinuses, ear cavities and anti inflammatory activity in upper respiratory tract organs help in faster resolution ,better antibiotic bioavailability and faster cure rates.

Male Genital Infections :

Restores microcirculation and augments antibiotic penetration in these organs which are known to produce poor antibiotic availability.

Dermatology :

Used in acute painful inflamed dermatoses.

Dentistry :

Helps better controll over dental infections.

Obstetrics & Gynaecology :

The anti inflammatory activity helps in resolution of post partum haematomas. breast engorgements, and pregnancy related thrombophlebitis,

Pharmacological action

Anti-inflammatory and anti-edematous actions :

Serratiopeptidase causes fibrin and bradykinin hydrolysis, without affecting human proteins such as albumin and alpha- or gamma-globulins. Effect on the lysis and removal of mucous secretion from the respiratory tract: SEPLIX reduces the viscosity and the volume of secretions.

Effects on the transfer of antibiotics to the infection site: SEPLIX enhances the transfer of antibiotics to the infection site.

Pharmacodynamics :

enzyme therapy with anti-inflammatory, anti-edematous and fluidifying action on the locomotive and respiratory systems.

Pharmacokinetics :

following oral administration to experimental animal, peak plasma concentrations of SEPLIX were achieved within less than one hour, the highest concentrations being found in the lymph. All of the substance was absorbed by the lymph within 6 hours following administration and increased in a dose-dependent fashion.

Dosage :

Therapy for adults only: the usual recommended dose is one tablet taken orally 3 times daily with meals. This dose may be increased according to the severity of the condition.

Precautions and warnings :

if the patient experiences an allergic reaction, administration of SEPLIX must be discontinued at once and treatment should not be reinstituted. The administration of SEPLIX to patients with severe liver impairment and coagulopathies should be assessed carefully.Regular monitoring is warranted in patients receiving anticoagulants. If the patient develops mucous-purulent expectorations, fever or chronic pulmonary disease, the therapy to be followed should be reconsidered. It should be remembered that productive cough is a fundamental component of the broncho pulmonary defense, therefore, combined administration of mucolytics and antitussives and/or secretion reducing substances (atropinic drugs) is irrational.

Embryogenesis and mutagenesis :

animal studies failed to show deleterious effects on these functions.

Pregnancy :

there is no clinical information available; therefore, this drug should not be administered during pregnancy. Lactation: there is no clinical information available; therefore, this drug should not be administered to breastfeeding women.

Adverse reactions :

occasional gastrointestinal disorders, including anorexia, nausea or epigastric pain, which are generally well tolerated and do not require drug discontinuation. Rare cases of nose bleeding and heamoptoic sputum have been reported.

Contraindications :

hypersensitivity to any component of the formula.